{"entity":{"id":"idea-prostate-plasticity-surveillance-before-it-is-neuroendocrine","kind":"idea","name":"Watch for the cancer changing cell type before the biopsy says neuroendocrine, and act on it","aka":["lineage plasticity surveillance prostate","TP53 RB1 loss monitoring prostate","pre-emptive platinum neuroendocrine prostate"],"tldr":"In a minority of men, prostate cancer escapes hormone drugs by becoming a different kind of cell that no longer needs the androgen receptor. By the time a biopsy shows it, the treatment options are almost gone. The genetic changes that allow the switch are detectable years earlier, and nobody is looking for them.","summary":"Mu and Ku showed in 2017 that combined loss of TP53 and RB1 function enables prostate cancer cells to shift from androgen receptor-dependent luminal cells to androgen receptor-independent basal-like cells, mediated by SOX2, and that restoring the tumour suppressors reverses it in the laboratory. Beltran had already shown that neuroendocrine prostate cancer arises by divergent clonal evolution from the same tumour rather than as a separate disease. Aggarwal found treatment-emergent small-cell neuroendocrine carcinoma in 17 percent of metastatic biopsies in a prospective cohort. Chung found RB1 alteration enriched in metastatic over primary samples.\n\nThe enabling lesions are therefore known, detectable in circulating tumour DNA, and present before the phenotype changes. What is missing is any protocol that uses them. A man with combined TP53 and RB1 loss who is started on a third androgen receptor-directed line is being given a treatment his tumour is predisposed to escape by the one route that leads nowhere. The proposal is a two-part programme: serial circulating tumour DNA genotyping for TP53 and RB1 status, plus a plasma transcriptional readout of neuroendocrine identity, in men starting an androgen receptor pathway inhibitor for castration-resistant disease; and a randomised test of whether men who convert should switch to platinum-based chemotherapy or a neuroendocrine-directed agent at conversion rather than at biopsy-proven transformation.\n\nWhat any of this means for someone treated in Britain, from the screening committee's position and the NICE appraisals to scanner and radiotherapy capacity, waiting times and how to reach a trial, is on the UK and NHS pathway page for prostate cancer.","asOf":"2026-09-25","links":[],"tags":["prostate-evidence"],"related":["idea-bio1-cfrna-plasticity-tracking","idea-bio1-ctc-derived-explants","prostate-roadmap","ctdna-tests"],"cancers":["prostate","prostate-mcrpc","prostate-nepc"],"sections":["diagnostics","targeted-therapy","chemotherapy"],"technologies":["liquid-biopsy","ngs"],"targets":["tp53","rb1","androgen-receptor"],"drugs":["carboplatin","cisplatin","enzalutamide","abiraterone"],"companies":[],"institutions":[],"pathways":[],"terms":["ctdna","castration-resistance","neuroendocrine-differentiation"],"trials":[],"people":[],"bottlenecks":["b-resistance","b-tumor-heterogeneity","b-rare-cancers","b-biomarker-validation","b-undruggable-targets"],"keyPapers":["paper-mu-sox2-lineage-plasticity-science-2017","paper-ku-rb1-trp53-lineage-plasticity-science-2017","paper-beltran-nepc-divergent-evolution-nat-med-2016","paper-aggarwal-t-sccpc-jco-2018","paper-rubin-mol-cell","paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"In men with castration-resistant prostate cancer, combined TP53 and RB1 loss detected in circulating tumour DNA identifies, months before any histological change, the group in whom further androgen receptor-directed therapy will fail quickly, and switching that group to platinum-based or lineage-directed treatment at the point of molecular conversion rather than at biopsy-proven neuroendocrine transformation improves overall survival.","rationale":"The mechanism is established in models and the frequency is established in patients: 17 percent of metastatic biopsies in Aggarwal's cohort were treatment-emergent small-cell neuroendocrine carcinoma, a diagnosis with a median survival measured in months and no approved treatment. The enabling genotype is measurable without a biopsy. And the current pathway, which waits for a clinical suspicion strong enough to justify re-biopsying a man with bone-predominant disease, guarantees that the diagnosis is made late: the trigger for suspicion is usually visceral metastasis or a rising tumour burden with a flat prostate-specific antigen, both of which are late events. Every element of the test exists; none of them is sequenced together prospectively.","test":"A prospective cohort with an embedded randomisation. Enrol men starting an androgen receptor pathway inhibitor for castration-resistant disease; collect plasma at baseline and at each cycle for targeted circulating tumour DNA sequencing of TP53, RB1 and PTEN and for a neuroendocrine transcriptional signature; biopsy at progression where safe to establish the histological reference. The observational phase measures how far in advance molecular conversion precedes histological transformation and its positive predictive value. Men who convert are then randomised to immediate platinum-based chemotherapy against continued standard sequencing with treatment change at histological transformation, with overall survival as the primary endpoint. Four years to the lead-time answer, seven to the randomised one.","maturity":"preclinical-evidence","actor":"research","cost":"large","horizonYears":7},"route":"/ideas/idea-prostate-plasticity-surveillance-before-it-is-neuroendocrine/","neighbours":{"idea":[{"id":"idea-bio1-arv7-degrader","kind":"idea","name":"Destroy the truncated androgen receptor that hormone drugs cannot touch","route":"/ideas/idea-bio1-arv7-degrader/"},{"id":"idea-bio1-cfrna-plasticity-tracking","kind":"idea","name":"Detect tumours changing cell type from RNA in the blood","route":"/ideas/idea-bio1-cfrna-plasticity-tracking/"},{"id":"idea-bio1-ctc-derived-explants","kind":"idea","name":"Grow models from tumour cells in the blood when a biopsy is impossible","route":"/ideas/idea-bio1-ctc-derived-explants/"}],"roadmap":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/"},{"id":"prostate-roadmap","kind":"roadmap","name":"Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch","route":"/roadmaps/prostate-roadmap/"}],"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate-nepc","kind":"cancer","name":"Neuroendocrine and small-cell prostate cancer","route":"/cancers/prostate-nepc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/"},{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"}],"term":[{"id":"castration-resistance","kind":"term","name":"Castration-resistant prostate cancer (CRPC)","route":"/terms/castration-resistance/"},{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"neuroendocrine-differentiation","kind":"term","name":"Neuroendocrine differentiation in prostate cancer","route":"/terms/neuroendocrine-differentiation/"},{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/"}],"target":[{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/"},{"id":"rb1","kind":"target","name":"RB1","route":"/targets/rb1/"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/"}],"bottleneck":[{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/"},{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/"},{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"},{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/"},{"id":"b-tumor-heterogeneity","kind":"bottleneck","name":"Tumour heterogeneity and clonal evolution","route":"/bottlenecks/b-tumor-heterogeneity/"}],"paper":[{"id":"paper-aggarwal-t-sccpc-jco-2018","kind":"paper","name":"Clinical and genomic characterisation of treatment-emergent small-cell neuroendocrine prostate cancer","route":"/key-papers/paper-aggarwal-t-sccpc-jco-2018/"},{"id":"paper-beltran-nepc-divergent-evolution-nat-med-2016","kind":"paper","name":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","route":"/key-papers/paper-beltran-nepc-divergent-evolution-nat-med-2016/"},{"id":"paper-rubin-mol-cell","kind":"paper","name":"Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers","route":"/key-papers/paper-rubin-mol-cell/"},{"id":"paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019","kind":"paper","name":"Prospective comprehensive genomic profiling of 3,476 primary and metastatic prostate tumours","route":"/key-papers/paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019/"},{"id":"paper-ku-rb1-trp53-lineage-plasticity-science-2017","kind":"paper","name":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis and antiandrogen resistance","route":"/key-papers/paper-ku-rb1-trp53-lineage-plasticity-science-2017/"},{"id":"paper-mu-sox2-lineage-plasticity-science-2017","kind":"paper","name":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","route":"/key-papers/paper-mu-sox2-lineage-plasticity-science-2017/"}]}}